HK Movers | Biopharma Company Vigonvita Soars 134% in Hong Kong's Grey Market Trading

Tiger Newspress

11/05

Biopharmaceutical company Vigonvita Life Sciences soared 134% in Hong Kong’s grey market trading.

Vigonvita Life Sciences develops biomedicine. The Company produces and sells innovative small molecule drugs, anti-viral drugs, and other products. Vigonvita Life Sciences markets its products primarily throughout China with limited overseas.

Vigonvita reportedly oversubscribed by 4,974 times through margin financing, and priced near the upper limit at HKD33.37 per share.

With a target issuance of 17.598 million shares, it is expected to raise HKD587 million. This round of IPO does not involve a clawback regime. The stock is anticipated to officially list tomorrow (6th).

Retail investors shared images on social media, indicating that even after splashing HKD30.214 million for maximum subscription of 879,800 shares, they still failed to secure a lot of 200 shares, marking the 9th instance under the new clawback regime.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1174827669"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1174827669\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1174827669?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 16:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1174827669","market":"hk","top_or_hot":-1,"title":"HK Movers | Biopharma Company Vigonvita Soars 134% in Hong Kong's Grey Market Trading","media":"Tiger Newspress","content":"<html><head></head><body><p>Biopharmaceutical company Vigonvita Life Sciences soared 134% in Hong Kong’s grey market trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3852f8d6a146598a14c2f3937d41429d\" title=\"\" tg-width=\"960\" tg-height=\"612\"/></p><p>Vigonvita Life Sciences develops biomedicine. The Company produces and sells innovative small molecule drugs, anti-viral drugs, and other products. Vigonvita Life Sciences markets its products primarily throughout China with limited overseas.</p><p>Vigonvita reportedly oversubscribed by 4,974 times through margin financing, and priced near the upper limit at HKD33.37 per share.<br/><br/>With a target issuance of 17.598 million shares, it is expected to raise HKD587 million. This round of IPO does not involve a clawback regime. The stock is anticipated to officially list tomorrow (6th).</p><p>Retail investors shared images on social media, indicating that even after splashing HKD30.214 million for maximum subscription of 879,800 shares, they still failed to secure a lot of 200 shares, marking the 9th instance under the new clawback regime.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Movers | Biopharma Company Vigonvita Soars 134% in Hong Kong's Grey Market Trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Movers | Biopharma Company Vigonvita Soars 134% in Hong Kong's Grey Market Trading\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2025-11-05 16:19</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><head></head><body><p>Biopharmaceutical company Vigonvita Life Sciences soared 134% in Hong Kong’s grey market trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/3852f8d6a146598a14c2f3937d41429d\" title=\"\" tg-width=\"960\" tg-height=\"612\"/></p><p>Vigonvita Life Sciences develops biomedicine. The Company produces and sells innovative small molecule drugs, anti-viral drugs, and other products. Vigonvita Life Sciences markets its products primarily throughout China with limited overseas.</p><p>Vigonvita reportedly oversubscribed by 4,974 times through margin financing, and priced near the upper limit at HKD33.37 per share.<br/><br/>With a target issuance of 17.598 million shares, it is expected to raise HKD587 million. This round of IPO does not involve a clawback regime. The stock is anticipated to officially list tomorrow (6th).</p><p>Retail investors shared images on social media, indicating that even after splashing HKD30.214 million for maximum subscription of 879,800 shares, they still failed to secure a lot of 200 shares, marking the 9th instance under the new clawback regime.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02630","symbol_name":"旺山旺水-B","start_time":0,"source_url":"","article_id":"1174827669","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1174827669","pubTimestamp":1762330797,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"Vigonvita stock soared 134% in Hong Kong’s grey market trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02630":"旺山旺水-B"},"translate_title":"HK Movers|生物制药公司Vigonvita在香港灰色市场交易中飙升134%","themeId":"c9a0abbe225b61c5dcb2243713c8d063","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02630":2},"content_text":"Biopharmaceutical company Vigonvita Life Sciences soared 134% in Hong Kong’s grey market trading.Vigonvita Life Sciences develops biomedicine. The Company produces and sells innovative small molecule drugs, anti-viral drugs, and other products. Vigonvita Life Sciences markets its products primarily throughout China with limited overseas.Vigonvita reportedly oversubscribed by 4,974 times through margin financing, and priced near the upper limit at HKD33.37 per share.With a target issuance of 17.598 million shares, it is expected to raise HKD587 million. This round of IPO does not involve a clawback regime. The stock is anticipated to officially list tomorrow (6th).Retail investors shared images on social media, indicating that even after splashing HKD30.214 million for maximum subscription of 879,800 shares, they still failed to secure a lot of 200 shares, marking the 9th instance under the new clawback regime.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}